These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36286849)

  • 1. [Clinical significance of serum levels of osteoproteherin and sclerostin in assessment of vascular calcification in chronic kidney disease stage 3-5].
    Dzgoeva FU; Remizov OV; Botcieva VK; Goloeva VG; Malakhova NG; Ikoeva ZR
    Ter Arkh; 2022 Aug; 94(6):731-737. PubMed ID: 36286849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
    Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
    Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
    Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
    Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease.
    Zeng C; Guo C; Cai J; Tang C; Dong Z
    Diab Vasc Dis Res; 2018 Mar; 15(2):99-105. PubMed ID: 29168393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease.
    Ji YQ; Guan LN; Yu SX; Yin PY; Shen XQ; Sun ZW; Liu J; Lv W; Yu GP; Ren C
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8822-8829. PubMed ID: 30575924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis and vascular calcification in rheumatoid arthritis - the role of osteoprotegerin and sclerostin].
    Krajewska-Włodarczyk M; Stompór T
    Pol Merkur Lekarski; 2017 Jul; 43(253):41-47. PubMed ID: 28805201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D.
    Wang XR; Yuan L; Zhang JJ; Hao L; Wang DG
    Nephrology (Carlton); 2017 Apr; 22(4):286-292. PubMed ID: 27165564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin: Another vascular calcification inhibitor?
    Claes KJ; Viaene L; Heye S; Meijers B; d'Haese P; Evenepoel P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3221-8. PubMed ID: 23788689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease.
    Yadav AK; Kumar V; Banerjee D; Gupta KL; Jha V
    J Steroid Biochem Mol Biol; 2018 Jun; 180():15-18. PubMed ID: 29331722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.
    Gršković A; Ćelić T; Španjol J; Markić D; Devčić B; Bobinac D; Rački S
    Acta Clin Croat; 2023 Jul; 62(Suppl2):46-52. PubMed ID: 38966016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of uremic toxin indoxyl sulfate and inflammation in the development of vascular calcification and cardiovascular complications in stage C3-C5D chronic kidney disease].
    Dzgoeva FU; Remizov OV; Goloeva VG; Ikoeva ZR
    Ter Arkh; 2023 Aug; 95(6):468-474. PubMed ID: 38158965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [End products of glycation (AGEs) and inflammation in the clinic of cardiovascular complications and vascular calcification at different stages of chronic kidney disease (G1-G5D)].
    Fatima DU; Remizov OV; Ikoeva ZR; Tedeeva IV; Gusalov AA; Goloeva VG
    Ter Arkh; 2024 Jul; 96(6):593-599. PubMed ID: 39106500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study.
    Hsu BG; Liou HH; Lee CJ; Chen YC; Ho GJ; Lee MC
    Medicine (Baltimore); 2016 Apr; 95(15):e3300. PubMed ID: 27082570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sclerostin: a new biomarker of interest in nephrology].
    Pelletier S; Jean G; Fouque D;
    Ann Biol Clin (Paris); 2015; 73(3):305-13. PubMed ID: 26069067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
    Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
    Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients.
    Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E
    Nephron; 2016; 132(3):181-90. PubMed ID: 26890570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!
    Brandenburg VM; Verhulst A; Babler A; D'Haese PC; Evenepoel P; Kaesler N
    Nephrol Dial Transplant; 2019 Mar; 34(3):408-414. PubMed ID: 29846712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.